argenex (ARGX) Expected to Announce Earnings on Thursday

argenex (NASDAQ:ARGX) is projected to announce its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect argenex to post earnings of $6.05 per share for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

argenex Stock Up 0.2%

Shares of NASDAQ:ARGX opened at $845.35 on Thursday. argenex has a 52 week low of $510.05 and a 52 week high of $934.62. The company has a market capitalization of $52.31 billion, a price-to-earnings ratio of 36.30, a price-to-earnings-growth ratio of 0.73 and a beta of 0.37. The firm has a 50 day moving average of $832.74 and a 200 day moving average of $804.51.

Institutional Investors Weigh In On argenex

Institutional investors and hedge funds have recently modified their holdings of the company. Wellington Management Group LLP raised its holdings in argenex by 80.1% in the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock valued at $538,408,000 after acquiring an additional 324,653 shares during the last quarter. Two Sigma Investments LP lifted its holdings in shares of argenex by 570.3% in the 3rd quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after purchasing an additional 250,278 shares during the last quarter. Woodline Partners LP increased its stake in shares of argenex by 320.8% in the third quarter. Woodline Partners LP now owns 169,476 shares of the company’s stock valued at $124,999,000 after purchasing an additional 129,205 shares during the period. Morgan Stanley raised its holdings in shares of argenex by 19.2% during the fourth quarter. Morgan Stanley now owns 518,852 shares of the company’s stock valued at $436,331,000 after buying an additional 83,746 shares during the last quarter. Finally, Balyasny Asset Management L.P. raised its holdings in shares of argenex by 826.6% during the second quarter. Balyasny Asset Management L.P. now owns 89,296 shares of the company’s stock valued at $49,222,000 after buying an additional 79,659 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ARGX. Wall Street Zen cut shares of argenex from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Royal Bank Of Canada raised their price target on shares of argenex from $860.00 to $925.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Piper Sandler boosted their price objective on argenex from $820.00 to $930.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Truist Financial increased their target price on argenex from $950.00 to $1,030.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Finally, Wells Fargo & Company boosted their price objective on shares of argenex from $1,264.00 to $1,317.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, argenex has an average rating of “Moderate Buy” and a consensus target price of $986.78.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.